Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 44.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,848 shares of the biotechnology company's stock after selling 4,587 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Ascendis Pharma A/S were worth $911,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 12.0% during the first quarter. Envestnet Asset Management Inc. now owns 11,851 shares of the biotechnology company's stock worth $1,847,000 after purchasing an additional 1,274 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth $420,000. GF Fund Management CO. LTD. lifted its holdings in shares of Ascendis Pharma A/S by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock worth $241,000 after purchasing an additional 278 shares during the period. New Wave Wealth Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth $222,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Ascendis Pharma A/S by 24.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 189,613 shares of the biotechnology company's stock worth $28,713,000 after purchasing an additional 36,875 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Oppenheimer reissued an "outperform" rating and set a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Citigroup lifted their price target on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research note on Friday. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $223.07.

Ascendis Pharma A/S Trading Down 0.1%

ASND traded down $0.14 during trading hours on Tuesday, hitting $174.75. The company's stock had a trading volume of 276,916 shares, compared to its average volume of 504,615. The business's 50-day moving average price is $168.27 and its 200-day moving average price is $153.60. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The stock has a market cap of $10.68 billion, a price-to-earnings ratio of -27.83 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.